Violetta Cotreau Net Worth

The estimated Net Worth of Violetta Cotreau is at least $63.8 millier dollars as of 28 February 2022. Ms Cotreau owns over 3,946 units of Akebia Therapeutics stock worth over $41,934 and over the last 4 years she sold AKBA stock worth over $21,841.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms Cotreau AKBA stock SEC Form 4 insiders trading

Ms has made over 2 trades of the Akebia Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 3,946 units of AKBA stock worth $8,484 on 28 February 2022.

The largest trade she's ever made was selling 5,833 units of Akebia Therapeutics stock on 3 January 2022 worth over $13,358. On average, Ms trades about 2,445 units every 14 days since 2021. As of 28 February 2022 she still owns at least 29,121 units of Akebia Therapeutics stock.

You can see the complete history of Ms Cotreau stock trades at the bottom of the page.

Ms. Violetta Cotreau biography

Violetta Cotreau is the Sr. VP, Chief Accounting Officer & Principal Accounting Officer at Akebia Therapeutics.

How old is Ms Cotreau?

Ms Cotreau is 48, she's been the Sr. VP et Chief Accounting Officer & Principal Accounting Officer of Akebia Therapeutics since . There are 12 older and 5 younger executives at Akebia Therapeutics. The oldest executive at Akebia Therapeutics Inc. is Adrian Adams, 69, who is the Independent Chairman of the Board.

What's Ms Cotreau's mailing address?

Violetta's mailing address filed with the SEC is C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE, MA, 02142.

Insiders trading at Akebia Therapeutics

Over the last 11 years, insiders at Akebia Therapeutics have traded over $3,056,393 worth of Akebia Therapeutics stock and bought 2,141,907 units worth $27,915,834 . The most active insiders traders include Holdings A/S Novo, Muneer A Satter et Mark J Enyedy. On average, Akebia Therapeutics executives and independent directors trade stock every 28 days with the average trade being worth of $43,534. The most recent stock trade was executed by Nicole R. Hadas on 13 May 2024, trading 12,016 units of AKBA stock currently worth $15,140.

What does Akebia Therapeutics do?

akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.

Complete history of Ms Cotreau stock trades at Akebia Therapeutics

Akebia Therapeutics executives and stock owners

Akebia Therapeutics executives and other stock owners filed with the SEC include:

• John Butler,
  President, Chief Executive Officer, Director
• Michel Dahan,
  Chief Operating Officer, Senior Vice President
• Nicole Hadas,
  Senior Vice President, Chief Legal Officer, Corporate Secretary
• Dell Faulkingham,
  Senior Vice President, Chief Commercial Officer
• John P. Butler MBA,
  CEO, Pres & Director
• Dr. Steven Keith Burke,
  Sr. VP of R&D and Chief Medical Officer
• Dell Faulkingham,
  Sr. VP & Chief Commercial Officer
• Michel Dahan,
  Sr. VP & COO
• Jason A. Amello,
  Exec. Officer
• Adrian Adams,
  Independent Chairman of the Board
• Michael Rogers,
  Independent Director
• Maxine Gowen,
  Independent Director
• Michael Heffernan,
  Independent Director
• Cynthia Smith,
  Independent Director
• Mark Enyedy,
  Independent Director
• Steven Gilman,
  Independent Director
• Kristen Sheppard,
  Vice President, Investor Relations
• Myles Wolf,
  Independent Director
• Steven Burke,
  Senior Vice President, Chief Medical Officer
• David Spellman,
  Chief Financial Officer, Senior Vice President, Treasurer
• Douglas Jermasek M.B.A.,
  VP of Marketing & Strategy
• Mercedes Carrasco,
  Director of Corp. Communications
• Nicole R. Hadas,
  Sr. VP, Chief Legal Officer & Sec.
• Violetta Cotreau,
  Sr. VP, Chief Accounting Officer & Principal Accounting Officer
• Scott A Canute,
  
• Duane Nash,
  Director
• Ronald C Jr Renaud,
  Director
• Muneer A Satter,
  Director
• Michael D. Clayman,
  Director
• Bradley Maroni,
  SVP & Chief Medical Officer
• Anupam Dalal,
  Director
• Michael S Wyzga,
  Director
• Rita Jain,
  SVP, Chief Medical Officer
• Karen L Tubridy,
  SVP, Chief Development Officer
• Leanne M Zumwalt,
  
• Ron Frieson,
  
• Jodie Pope Morrison,
  
• Robert Shalwitz,
  Chief Medical Officer
• Bioventures Ltd Novartis,
  10% owner
• Holdings A/S Novo,
  10% owner
• Violetta Cotreau,
  SVP, Chief Accounting Officer
• Jason Amello,
  SVP, CFO & Treasurer
• Ellen Snow,
  SVP, CFO and Treasurer
• Nicholas Grund,
  Chief Commercial Officer
• Richard C Malabre,
  Chief Accounting Officer
• Erik Ostrowski,
  SVP, CFO, CBO & Treasurer